Quantcortex Research Model
fundamental
Illustrative Model Composition (Hypothetical)
Yearly Performance & Rebalance Activity
Calendar-year returns of the research model alongside how often it triggered rebalances each year.
📅 Portfolio Snapshots (weekly)
Week-by-week composition of the research model. Green border marks newly added holdings (with top contributing signals), red marks removed positions.
Symbol Trade Chart (Buy/Sell)
Research Model Signal Change Log
Analytical signals driving exposure adjustments. Each entry links to the dedicated rebalance page.
📰 Latest Market News & Updates
Curated news for the latest model holdings and macro headlines that may affect the broader market.
- GSNeutralMarketBeatEmpirical Finance LLC Purchases 72,073 Shares of Dollar Tree, Inc. $DLTR
Empirical Finance LLC significantly increased its stake in Dollar Tree (NASDAQ:DLTR) by 983.9% in the second quarter, acquiring 72,073 additional shares to own a total of 79,398 shares valued at $9.46 million. This comes as Dollar Tree repo
2026-09-08T23:28:53.000Z - MRKNeutralMarketBeatAllworth Financial LP Decreases Holdings in Merck & Co., Inc. $MRK
Allworth Financial LP reduced its stake in Merck & Co., Inc. by 20.7% in Q2, selling 54,355 shares to own 208,546 shares valued at $26.798 million. Despite this, other institutional investors increased their holdings, and the company's stoc
2026-09-08T23:17:49.000Z - CBNeutralYahoo! Finance CanadaMulti-Line Insurance Stocks Q2 Teardown: Chubb (NYSE:CB) Vs The Rest
The article analyzes the Q2 performance of multi-line insurance stocks, focusing on Chubb (NYSE:CB) and its competitors. It highlights that the sector experienced a slower Q2, with most companies missing revenue estimates and seeing stock p
2026-09-08T23:09:00.000Z - GSPositiveYahoo FinanceGoldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
Goldman Sachs has added Vertex Pharmaceuticals (NASDAQ: VRTX) to its highest-conviction list, giving it a "buy" rating and a $653 price target. The article highlights Vertex's expanding portfolio beyond its successful cystic fibrosis drugs,
2026-09-08T22:42:39.000Z - LINPositiveBenzingaHere's How Much $100 Invested In Linde 10 Years Ago Would Be Worth Today
Linde (NASDAQ: LIN) has outperformed the market over the past decade, with a $100 investment 10 years ago now valued at $395.16, representing an annualized return of 14.78%. This performance highlights the significant impact of compounded r
2026-09-08T21:19:05.000Z - JNJPositiveACCESS NewswireProtagonist Therapeutics Announces $300 Million Share Repurchase Program
Protagonist Therapeutics has announced that its Board of Directors has authorized a share repurchase program of up to $300 million of its outstanding common stock. The company plans to fund these repurchases using its existing cash, cash eq
2026-09-08T19:52:58.000Z - GSNeutralInvesting.comeBay at Goldman Sachs Communacopia + Technology Conference: growth shift
eBay presented its growth strategy at the Goldman Sachs Communacopia + Technology Conference, highlighting its focus on specific categories like C2C, recommerce, and collectibles, which are growing at over 20%. The company emphasized the si
2026-09-08T19:46:14.000Z - AMGNNegativeTradingKeyBristol-Myers Squibb Co Stock (BMY) Moved Down by 3.25% on Sep 8: Facts Behind the Movement
Bristol-Myers Squibb (BMY) stock declined by 3.25% on September 8th, primarily due to investor profit-taking despite positive Phase 2 trial results for arlocabtagene autoleucel. Investors reacted cautiously to unspecified regulatory timelin
2026-09-08T18:49:46.000Z
- NeutralbusinessNvidia faces Justice Department probe over $20B licensing deal with Groq
The Justice Department is investigating Nvidia's $20 billion licensing agreement with AI chip startup Groq to determine if it was structured to bypass antitrust review. This inquiry is part of a broader effort by the …
6 minutes ago - NeutralTheBlockCoBlackRock's IBIT ETF sees $120M in outflows as Bitcoin ETFs struggle
On Wednesday, spot bitcoin ETFs experienced significant outflows, totaling $120.2 million, attributed to redemptions from major funds including BlackRock's IBIT and Grayscale's GBTC. In contrast, spot ether ETFs repor…
20 minutes ago - NeutralbusinessEuropean Commission advances 'Made in Europe' initiative
The European Commission announced new measures today that advance its “Made in Europe” strategy, aimed at prioritizing local industries and enhancing economic independence. This move aligns with recent proposals that …
31 minutes ago - NeutralFirstSquawkMinoru Kihara emphasizes abduction issue as key to North Korea summit
Japan's Chief Cabinet Secretary Kihara emphasized that addressing the abduction issue is crucial for facilitating a summit with North Korea. Japanese officials maintain that the North Korean abductions of Japanese nat…
44 minutes ago - NeutralbusinessAustralia adjusts LNG export policies, replaces fixed requirements with annual cap
Australia has revised its approach to managing liquefied natural gas exports by easing plans that would have required exporters to reserve supplies for domestic users. The new policy replaces the previous mandatory do…
45 minutes ago - NeutralBBCWorldRussia outpaces Ukraine's air defenses with new jet-powered drones
Russia has been utilizing new jet-powered drones daily, surpassing Ukraine's air defenses and making it increasingly difficult for Ukrainian forces to intercept these advanced unmanned aerial vehicles. This developmen…
54 minutes ago
News headlines are aggregated from third-party providers for informational purposes only and do not constitute investment advice.
Weekly Rebalance Pages (66)
Showing 1-40 of 66 dedicated rebalance pages.
Important Disclosure
All information provided is for educational and informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security.
The content reflects hypothetical research models and simulations that are not intended for implementation and may not reflect actual trading results.
No information on this platform is tailored to the investment needs, financial situation, or objectives of any individual.
Past or simulated performance is not indicative of future results.